AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00
- £135.84m
- £132.17m
- £59.59m
- 15
- 8
- 100
- 32
REG - Allergy Therapeutics - Annual Report and Accounts Delayed
AnnouncementREG - Allergy Therapeutics - Director Resignation
AnnouncementREG - Allergy Therapeutics - Key updates on Grass MATA MPL and VLP Peanut
AnnouncementREG - Allergy Therapeutics - Appointment of Non-Executive Directors
AnnouncementREG - Allergy Therapeutics - Appointment of Interim CFO
AnnouncementREG - Allergy Therapeutics - Allergy to resume UK manufacturing production
AnnouncementREG - Allergy Therapeutics - Holding(s) in Company
AnnouncementREG - AIM - AIM Notice - 19/10/2022
AnnouncementREG - Allergy Therapeutics - Allergy Therapeutics – Result of GM
AnnouncementREG - Allergy Therapeutics - UK manufacturing update
AnnouncementRCS - Allergy Therapeutics - Allergy Therapeutics at Investor Meet Company
AnnouncementREG - Allergy Therapeutics - Unaudited Preliminary Results 2022
AnnouncementREG - Allergy Therapeutics - Subscription and Debt Financing
AnnouncementRCS - Allergy Therapeutics - Allergy Therapeutics at H.C. Wainwright Conference
AnnouncementREG - Allergy Therapeutics - Total Voting Rights
AnnouncementREG - Allergy Therapeutics - Block Listing Interim Review
AnnouncementREG - Allergy Therapeutics - Trading Update and Notice of Results
AnnouncementRCS - Allergy Therapeutics - Allergy Therapeutics at EAACI Congress 2022
AnnouncementREG - Allergy Therapeutics - Nick Wykeman to step down as CFO
Announcement